Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy

AIDS

Volumn 24, Issue 14, 2010, Pages 2193-2200

  Cressey, Tim R ^a,b,c   Jourdain, Gonzague ^a,b,c   Rawangban, Boonsong ^d   Varadisai, Supang ^e   Kongpanichkul, Rucha ^f   Sabsanong, Prapan ^g   Yuthavisuthi, Prapap ^h   Chirayus, Somnuk ⁱ   Ngo Giang Huong, Nicole ^a,b,c   Voramongkol, Nipunporn ^j   Pattarakulwanich, Somsak ^j   Lallemant, Marc ^a,b,c  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^d Nopparat Rajathanee Hospital   (Thailand)

^e Samutsakhon General Hospital   (Thailand)

^f Nakhonpathom Hospital   (Thailand)

^g Samutprakarn Hospital   (Thailand)

^h PRAPOKKLAO HOSPITAL   (Thailand)

ⁱ Vachira Phuket Hospital   (Thailand)

^j MINISTRY OF PUBLIC HEALTH   (Thailand)

more..

Author keywords

lopinavir; pharmacokinetics; pregnancy; prevention of mother tochild transmission of HIV; viral load

Indexed keywords

LOPINAVIR PLUS RITONAVIR; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DIARRHEA; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; THAILAND; THIRD TRIMESTER PREGNANCY; VIRUS LOAD; VIRUS TRANSMISSION; VOMITING;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; THAILAND; VIRAL LOAD; YOUNG ADULT; ZIDOVUDINE;

EID: 77956232308     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833ce57d     Document Type: Article

References (26)

1. WHO. Use of antiretroviral drugs for treating pregnant women and preventing HIV Infection in infants. Geneva, Switzerland: World Health Organization. 2009.
2. Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, et al. Reduced lopinavir exposure during pregnancy. AIDS 2006; 20:1931-1939.
3. Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2008; 49:485-491.
4. Best BM, Stek AM, Hu C, Burchett SK, Rossi SS, Smith E, et al. High-dose lopinavir and standard dose emtricitabine pharma-cokinetics during pregnancy and postpartum [poster #629]. 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts, USA; 2008.
5. Lyons F, Lechelt M, De Ruiter A. Steady-state lopinavir levels in third trimester of pregnancy. AIDS 2007; 21:1053-1054.
6. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS 2007; 21:643-645.
7. Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-393.
8. Kaletra Package Insert (Product Ladeling). Abbott Park, Illinois, USA: Abbott Laboratories; 2005.
9. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15:F1-F9.
10. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saqui-navir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxy-metabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25:393-399.
11. Holland DT, DiFrancesco R, Connor JD, Morse GD. Quality assurance program for pharmacokinetic assay of antiretrovir-als: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004-a requirement for therapeutic drug monitoring. Ther Drug Monit 2006; 28:367-374.
12. Khuong-Josses MA, Boussairi A, Palette C, Mechali D. Lopinavir drug monitoring in 36 pregnant women [abstract #743]. 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007, Los Angeles, California, USA; 2007.
13. Peytavin G, Francois-Pierre S, CassardB, Truchis de P, Winter C, Visseaux B, et al. Reduced lopinavir exposure during pregnancy: a case-control study [abstract #579]. 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, California, USA; 2007.
14. Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, Pancharoen C, et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J 2005; 24:874-879.
15. Chiu YL, King MS, Li J, Klein CE, Hanna GJ. Trough lopinavir concentrations do not predict virologic response to lopinavir/ritonavir-based three-drug regimens in antiretroviral-naive patients [poster #38]. 8th International Workshop on Clinical Pharmacology of HIV Therapy, 16-18 April 2007; Budapest, Hungary; 2007.
16. van der Leur MR, Burger DM, la Porte CJ, Koopmans PP. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit 2006; 28:650-653.
17. Gibbons S, Back D, Khoo S. Variability in lopinavir concentrations in the clinical setting and factors affecting concentrations [abstract #37]. In: 8th International Workshop on Clinical Pharmacology of HIV Infection; 16-18 April 2007; Budapest, Hungary; 2007.
18. Bouillon-Pichault M, Jullien V, Piketty C, Viard JP, Morini JP, Chhun S, et al. A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and-experienced patients. Antivir Ther 2009; 14:923-929.
19. Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, et al. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med 2010; 11:232-238.
20. Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, et al. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics 2007; 8:227-235.
21. Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010; 20:112-120.
22. Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 2010; 20:217-230.
23. Klein CE, Chiu YL, Awni W, Zhu T, Heuser RS, Doan T, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr 2007; 44:401-410.
24. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28:1032-1035.
25. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002; 51:597-599.
26. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22:289-299.